Phaseline

Companies › Luye Pharma Group

Luye Pharma Group: clinical trials, targets and expected readouts

7 active drug programs in 8 registered trials: 4 Phase 1, 3 Phase 3, 1 Phase 2; Oncology, Neurology, Other, Metabolic and endocrine; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lurbinectedin
RNA polymerase II inhibitor; RNA-dependent transcription inhibitor
POLR2APhase 3Relapsed Small Cell Lung CancerDec 2027
LY01610
Topoisomerase I inhibitor (liposomal formulation)
TOP1Phase 3Relapsed Small Cell Lung CancerJun 2028
LY06006
RANKL inhibitor
TNFSF11Phase 3Osteoporosis, Postmenopausal–
LY01021–Phase 2Assisted Reproduction–
LPM6690176 (also: LY01024)–Phase 1Advanced Solid TumorFeb 2027
LPM3770164 sustained-release tablet–Phase 1Tardive Dyskinesia (TD)–
LY03020–Phase 1Schizophrenia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05853354LY06006Phase 3Osteoporosis, PostmenopausalMetabolic and endocrineJul 2025
NCT07292233LY03020Phase 1SchizophreniaNeurologyAug 2025
NCT06731868LPM3770164 sustained-release tabletPhase 1Tardive Dyskinesia (TD)NeurologyOct 2025
NCT07230652LY03020Phase 1SchizophreniaNeurologyDec 2025
NCT07236476LY01021Phase 2Assisted ReproductionOtherDec 2025
NCT06240546LPM6690176 (also: LY01024)Phase 1Advanced Solid TumorOncologyFeb 2027
NCT06496048LurbinectedinPhase 3Relapsed Small Cell Lung CancerOncologyDec 2027
NCT06128837LY01610Phase 3Relapsed Small Cell Lung CancerOncologyJun 2028

Targets

POLR2A (1) TNFSF11 (1) TOP1 (1)

Companies with the same targets

Merck & Co. (MSD) Daiichi Sankyo Gilead Sciences AstraZeneca Henan Genuine Biotech Senhwa Biosciences GSK Jiangsu Hansoh Pharmaceutical Qilu Pharmaceutical Amgen

Companies built like this

AB Science Guangzhou Lupeng Pharmaceutical Company Shanghai Pharmaceuticals Holding Debiopharm International GE Healthcare

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.